Partnering with Artax
Our pipeline of first-in-class Nck modulator candidates is fully proprietary, with a convincing clinical and preclinical data package. We reported clinical validation of Nck modulation with AX-158 in Phase 2a in psoriasis patients.
Novel mechanism of action effective across multiple diseases and strong composition of matter patent protection
Our pipeline of Nck modulators is breaking new ground across a wide array of T cell mediated autoimmune indications.
Interested in partnering with us? Get in touch!
We are interested in speaking with potential pharma partners about further development and commercialization of our first-in-class pipeline. Contact us at contact@artaxbiopharma.com
The latest news and publications from Artax
-
- Media
Artax Biopharma’s AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
-
- Scientific Publications
AX-158 Proof-of-Mechanism Safety Study: Evaluating a Novel T cell Receptor (TCR)
Signal Modulator in Patients with Mild-to-Moderate Plaque Psoriasis -
- Press Releases
Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting
First small molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically…